BLCM Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum's GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.

Company profile

Richard Fair
Fiscal year end
Former names
Bellicum Pharma Limited • Bellicum Pharma GmbH ...

BLCM stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 Aug 21
20 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.78M 21.78M 21.78M 21.78M 21.78M 21.78M
Cash burn (monthly) 2.6M 3.85M 2.6M 3.5M 2.6M 3.52M
Cash used (since last report) 9.59M 14.19M 9.56M 12.91M 9.57M 12.98M
Cash remaining 12.19M 7.59M 12.21M 8.87M 12.21M 8.8M
Runway (months of cash) 4.7 2.0 4.7 2.5 4.7 2.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Aug 21 Fair Richard A. Stock Option Common Stock Grant Acquire A No No 2.88 265,000 763.2K 265,000
1 Jul 21 Daly James M RSU Common Stock Grant Acquire A No No 0 809 0 809
1 Jul 21 Klimovsky Judith V RSU Common Stock Grant Acquire A No No 0 566 0 566
15 Jun 21 Brown James F Stock Option Common Stock Grant Acquire A No No 3.05 6,500 19.83K 6,500

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

18.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 30 29 +3.4%
Opened positions 4 6 -33.3%
Closed positions 3 13 -76.9%
Increased positions 4 5 -20.0%
Reduced positions 8 3 +166.7%
13F shares
Current Prev Q Change
Total value 5.13M 5.15M -0.3%
Total shares 1.56M 1.37M +13.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Ikarian Capital 500K $1.65M 0.0%
Vanguard 424.31K $1.4M +111.3%
Baker Bros. Advisors 249.12K $822K 0.0%
BLK Blackrock 74.77K $247K -29.2%
Geode Capital Management 58.66K $193K +86.8%
Boothbay Fund Management 53.04K $175K 0.0%
Citadel Advisors 33.62K $111K -37.8%
LPLA LPL Financial 29.46K $97K +76.4%
STT State Street 27.25K $90K NEW
AJU IB Investment 25.65K $85K 0.0%
Largest transactions
Shares Bought/sold Change
Vanguard 424.31K +223.52K +111.3%
BLK Blackrock 74.77K -30.85K -29.2%
Geode Capital Management 58.66K +27.26K +86.8%
STT State Street 27.25K +27.25K NEW
Citadel Advisors 33.62K -20.43K -37.8%
Acadian Asset Management 14.22K -18.37K -56.4%
BK Bank Of New York Mellon 0 -13.31K EXIT
Susquehanna Fundamental Investments 0 -13.3K EXIT
LPLA LPL Financial 29.46K +12.76K +76.4%
Squarepoint Ops 16.33K -11.59K -41.5%

Financial report summary

  • The FDA and other regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.
  • Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.
  • Our CID technology is novel and largely unproven.
  • Cell therapies are novel and present significant challenges.
  • Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.
  • Many of our current product candidates are in early stage clinical trials, and we may experience unfavorable results in the future.*
  • We may not be successful in our efforts to use and expand our CID platform to build a pipeline of product candidates and develop marketable products.
  • We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
  • Our business could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.*
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Any adverse developments that occur during any clinical trials conducted by academic investigators, our collaborators or other entities conducting clinical trials under independent INDs may affect our ability to obtain regulatory approval or commercialize our product candidates.
  • Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.*
  • Clinical trials are expensive, time-consuming and difficult to design and implement.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.*
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Workforce and expense reductions may have an adverse impact on our internal programs, our ability to hire and retain key personnel and may be distracting to management, and could harm our internal control over financial reporting.*
  • We oversee a complex manufacturing supply chain of cellular therapy product candidates, viral vectors and small molecule drugs.*
  • We have limited information available regarding the ultimate cost of our products, and cannot estimate what the cost of our products will be upon commercialization, should that occur.
  • Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.
  • A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.*
  • We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • If we are unable to identify a strategic partner for rivo-cel, we may not realize value from this asset and we will continue to incur substantial costs.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
  • We and our contractors utilize hazardous materials in our business operations, and any claims relating to improper handling, storage, or disposal of these materials could harm our business.
  • Our internal computer systems, or those used by our clinical investigators, contractors or consultants, may fail or suffer security breaches.
  • System outages, network disruptions and cyber-security threats could interrupt the operation of our business.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties and/or withdrawal of product approval if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.*
  • Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community.*
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.
  • Due to the novel nature of our technology and the small size of our target patient populations, we face uncertainty related to pricing and reimbursement for these product candidates.
  • We are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could harm our business.
  • We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, or collectively, Trade Laws. We can face serious consequences for violations.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
  • If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be able to compete effectively in our market.
  • Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.
  • We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • Obtaining and maintaining our patents depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent position could be reduced or eliminated for non-compliance with these requirements.
  • Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • The price of our stock is volatile and you could lose all or part of your investment.
  • As of December 31, 2019, we are no longer an “emerging growth company” and, as a result, are required to comply with increased disclosure and governance requirements.
  • Changes in accounting rules, assumptions and/or judgments could materially and adversely affect us.
  • Our consolidated financial statements, including our liabilities and statements of operations are subject to quarterly changes in our accounting of our outstanding Series 1 Preferred Stock, warrants and related option fee proceeds.
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our EIP and shelf registration statement, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • We completed a public offering of our Series 1 preferred stock on August 21, 2019 and are obligated to issue shares of Series 2 and Series 3 preferred stock in connection with the concurrent private placement, and if we are required to redeem shares of preferred stock, our cash position will be negatively impacted. In addition, we may not have sufficient funds to redeem such shares of preferred stock.
  • The issuance or sale of shares of our common stock, or rights to acquire shares of our common stock, including the issuance of our securities pursuant to our August 2019 private placement, could depress the trading price of our common stock.
  • Certain investors in the private placement will have the ability to control or significantly influence certain business decisions.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
Management Discussion
  • Item 2.         Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • This report contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipate,” “believe,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, Part I, Item 1A, “Risk Factors” in our Annual Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.
  • We are a clinical stage biopharmaceutical company focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. We are advancing CAR-T cell therapies, which are an innovative approach in which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors, or CARs. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better efficacy and safety outcomes than are seen with current cellular immunotherapies.
Content analysis
H.S. junior Avg
New words: argued, earned, immaterial, Maryland, MFN, misstatement, retention, similarly
Removed: Cadillac, halt, informed, insurer, Kuur, nonrefundable, package, permanently, University


Methods to Augment or Alter Signal Transduction
20 May 21
The technology relates generally to the field of immunology and relates in part to compositions and methods for activating cells, including, for example T cells that express chimeric antigen receptors or recombinant TCRs, and reducing cytotoxicity, using chimeric polypeptides including MyD88 and signaling domains of receptor mediators of costimulation.
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
2 Mar 21
The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides.
Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides
16 Feb 21
The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
12 Jan 21
The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.
Methods for Enhancing and Maintaining Car-t Cell Efficacy
4 Nov 20
The technology relates generally to the field of immunology and relates in part to compositions and methods for activating T cells and other cells resulting in an immune response against a target antigen.